SEC Filing Summary

David Young, President of Research & Development at Processa Pharmaceuticals, Inc., reported a transaction on April 30, 2026. He acquired 1706 shares of Common Stock at a price of $2.69 per share, increasing his post-transaction holdings to 13813 shares. Following this transaction, his direct ownership includes 1242 shares held through the Young-Plaisance Revocable Trust, 432 shares through Family Entities, and 742 shares through CorLyst, LLC.